Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report

Neuroimmunology Reports Pub Date : 2024-01-01 DOI:10.1016/j.nerep.2024.100212

Azusa Sunouchi , Ryota Amano , Ayumi Uchibori

{"title":"Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report","authors":"Azusa Sunouchi , Ryota Amano , Ayumi Uchibori","doi":"10.1016/j.nerep.2024.100212","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The first-line treatment for GBS is plasma exchange or intravenous immunoglobulin. In contrast, corticosteroids are not recommended for treating GBS. However, COVID-19–related Guillain–Barré syndrome occurs via mechanisms different from other infectious diseases.</p></div><div><h3>Case report</h3><p>A 63-year-old woman experienced back pain following COVID-19, progressing to numbness/weakness of the extremities, left peripheral facial nerve palsy, and abnormal sensation/allodynia in the face and extremities. Compound muscle action potentials showed severe temporal dispersion. Intravenous immunoglobulin administration slightly improved the lower limb muscle weakness and facial nerve palsy but was ineffective for the pain in the chest and back and numbness of the extremities. Three courses of intravenous methylprednisolone (IVMP) enabled the patient to walk unassisted.</p></div><div><h3>Conclusions</h3><p>This case is the first to demonstrate IVMP's effectiveness against COVID-19–related Guillain–Barré syndrome. Further studies are required to establish treatments for COVID-19–related Guillain–Barré syndrome.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"5 ","pages":"Article 100212"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X24000135/pdfft?md5=094fb0abd491cd217cd599c2d132a874&pid=1-s2.0-S2667257X24000135-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X24000135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The first-line treatment for GBS is plasma exchange or intravenous immunoglobulin. In contrast, corticosteroids are not recommended for treating GBS. However, COVID-19–related Guillain–Barré syndrome occurs via mechanisms different from other infectious diseases.

Case report

A 63-year-old woman experienced back pain following COVID-19, progressing to numbness/weakness of the extremities, left peripheral facial nerve palsy, and abnormal sensation/allodynia in the face and extremities. Compound muscle action potentials showed severe temporal dispersion. Intravenous immunoglobulin administration slightly improved the lower limb muscle weakness and facial nerve palsy but was ineffective for the pain in the chest and back and numbness of the extremities. Three courses of intravenous methylprednisolone (IVMP) enabled the patient to walk unassisted.

Conclusions

This case is the first to demonstrate IVMP's effectiveness against COVID-19–related Guillain–Barré syndrome. Further studies are required to establish treatments for COVID-19–related Guillain–Barré syndrome.

查看原文本刊更多论文

甲基强的松龙对 COVID-19 相关格林-巴利综合征的疗效：单个病例报告

背景治疗 GBS 的一线疗法是血浆置换或静脉注射免疫球蛋白。相比之下，治疗 GBS 不推荐使用皮质类固醇。病例报告：一名 63 岁的女性在感染 COVID-19 后出现背部疼痛，随后发展为四肢麻木/乏力、左侧外周面神经麻痹、面部和四肢感觉异常/全身失调。复合肌肉动作电位显示出严重的时间弥散。静脉注射免疫球蛋白略微改善了下肢肌无力和面神经麻痹，但对胸背部疼痛和四肢麻木无效。该病例首次证明了 IVMP 对 COVID-19 相关格林-巴利综合征的疗效。还需要进一步的研究来确定 COVID-19 相关格林-巴利综合征的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroimmunology Reports

自引率

0.00%

发文量